

Imperial College London
National Heart and Lung Institute
Dovehouse Street
London SW3 6LY

1 August 2012

Dear Committee


I write to formally congratulate you on a very thorough and detailed assessment of ivabradine for the use in chronic heart failure.

I fully endorse the recommendations in your provisional guidance, and think them clinically sensible and cautious. They will lead to the evidence-based use of ivabradine, without leading to any less usage of beta-blockade. I particularly endorse the recommendation that those with expertise in heart failure will assess the patient prior to the drug being prescribed, but uptitration can be performed by a GP with a special interest or a heart failure nurse specialist.

The report's assessment of cost-effectiveness also appears very sensible, and reflects the good value of money of this drug in the correct patients.

I would like to thank the committee for its handling of these issues, and in particular the sensible way it has dealt with the feedback on the reports from the invited clinical experts. I am very pleased that patients in England will be able to have access to this drug on the NHS.

Yours sincerely,



Professor Martin R Cowie MD MSc FRCP FRCP (Ed) FESC
Professor of Cardiology
Imperial College London (Royal Brompton Hospital) and Clinical Expert on behalf of the **British Cardiovascular Society**.

T: [REDACTED]
F: [REDACTED]
E: [REDACTED]